16
13
8
↑16
↓13
—8
Evidence suggests Iron mayincreaseVascular function.
34 studies (37 claims)
Conflicting evidence
Typical effective dose 525 (40.63–1000) mgacross 4 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| prenatal maternal iron deficiency | No effect - was not associated with | poor cognitive function | Human | children at age 1 year | Daily iron and folic acid supplements (specific dosage not mentioned). | Prenatal Iron Deficiency, Neonatal Ferritin, and Infant Cognitive Function.cited 31× |
| prenatal maternal iron deficiency | No effect - was not associated with | poor gross motor function | Human | children at age 1 year | Daily iron and folic acid supplements (specific dosage not mentioned). | Prenatal Iron Deficiency, Neonatal Ferritin, and Infant Cognitive Function.cited 31× |
| iron along with iodine | Increases - greater improvements | thyroid function and volume | Human | iodine- and iron-deficient populations | Not specified | The impact of common micronutrient deficiencies on iodine and thyroid metabolism: the evidence from human studies.cited 50× |
| iron supplementation | Decreases - has been associated with | deterioration of right ventricular function | Human | patients with PAH | Oral iron dosed three times a day; ferrous maltol dosed every other day. | Iron deficiency and pulmonary arterial hypertension.cited 6× |
| iron supplementation | Increases - improves | mental function | Human | iron-deficient adults | 3 oz (85 g) of beef or non-beef protein, 3 times weekly | Improvements in iron status and cognitive function in young women consuming beef or non-beef lunches.cited 22× |
| iron supplementation | No effect - not reversible | permanent alterations in brain structure and function | Human | NICU infants | Not available | Iron and Neurodevelopment in Preterm Infants: A Narrative Review.cited 15× |
| Iron supplementation | Increases - improve | several aspects of brain function | Human | iron deficient children | Not specified | New actions for old nutrients.cited 6× |
| intravenous iron therapy | Increases - suggests a potential positive impact on | kidney function | Human | patients with CRS | Not specified | Cardiorenal syndrome and iron supplementation-more benefits than risks: a narrative review.cited 1× |
| intravenous iron therapy | Increases - improvements in | renal function markers | Human | patients receiving intravenous iron therapy | Not specified | Cardiorenal syndrome and iron supplementation-more benefits than risks: a narrative review.cited 1× |
| Intravenous iron therapy | Increases - improve | physical function | Human | heart failure with reduced ejection fraction with iron deficiency | Not specified | Iron deficiency and iron therapy in heart failure and chronic kidney disease.cited 5× |
| Intravenous iron therapy | Increases - improves | physical function | Human | heart failure with reduced ejection fraction and iron deficiency | Not specified | Iron deficiency and iron therapy in heart failure and chronic kidney disease.cited 5× |
| intravenous iron therapy | Increases - leads to enhanced | physical function | Human | non-dialysis stage 3-4 CKD patients with iron deficiency but without anaemia | Not specified | The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.cited 4× |
| intravenous iron therapy | Increases - will address a substantial knowledge gap in the effects | physical function | Human | non-dialysis patients with CKD who are iron-deficient but not anaemic | Not specified | The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.cited 4× |
| changes in body iron levels | No effect - exert subtle effects | host immune function | Human | — | Not specified | Oral iron supplementation: Potential implications for the gut microbiome and metabolome in patients with CKD.cited 45× |
| gold-iron oxide (Au-Fe3O4@PEG) nanourchins (NUs) | Decreases - disrupt mitochondrial function | mitochondrial function | Molecular | A549 lung cancer cells | Not specified. | Targeted Cancer Therapy with Gold-Iron Oxide Nanourchins: Inducing Oxidative Stress, Paraptosis, and Sensitizing Tumor Cells to Cisplatin. |
| oral iron supplementation | Increases - has been shown to improve | sexual function | Human | women with IDA | Not specified (ferrous sulphate and prolonged-release formulations mentioned). | Iron deficiency and sexual dysfunction in women.cited 2× |
| IV iron treatment | No effect - provide important information on the short-term effects | measures of exercise capacity, quality of life and mechanistic data on myocardial structure and function | Human | CKD patients with ID without anaemia | 1,000 mg IV ferric derisomaltose (single dose). | Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease.cited 8× |
| IV iron supplementation | No effect - compare the effects | functional status, and in addition cardiac structure and function | Human | iron-deficient but not anaemic patients with established CKD stages 3b-5 | 1,000 mg IV ferric derisomaltose (single dose). | Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease.cited 8× |
| intravenous (IV) iron treatment | Increases - lead to improvement | heart function and well-being | Human | people with ID and CKD | 1,000 mg IV ferric derisomaltose (single dose). | Protocol and Baseline Data of a Multicentre Prospective Double-Blinded Randomized Study of Intravenous Iron on Functional Status in Patients with Chronic Kidney Disease.cited 8× |
| iron plus folic acid supplementation | No effect - had no effect overall | intellectual, motor, and executive function | Human | children 12 to 35 months of age at supplementation and 7 to 9 years of age at testing in rural Nepal | 12.5 mg iron and 50 μg folic acid | Preschool micronutrient supplementation effects on intellectual and motor function in school-aged Nepalese children.cited 46× |
| iron plus folic acid or zinc supplementation | No effect - had no effect | aspects of intellectual, executive, and motor function | Human | children 12 to 35 months of age at supplementation and 7 to 9 years of age at testing in rural Nepal | 12.5 mg iron and 50 μg folic acid | Preschool micronutrient supplementation effects on intellectual and motor function in school-aged Nepalese children.cited 46× |
| Iron oxides nanoparticles (FeO NPs) | Increases - improved | cognitive function | Animal | iron-deficient rats | — | Metabolomics reveals the role of acetyl-l-carnitine metabolism in γ-Fe |
| Iron oxides nanoparticles (FeO NPs) | No effect - showed no significant change | kidney function parameters | Animal | iron-deficient rats | — | Metabolomics reveals the role of acetyl-l-carnitine metabolism in γ-Fe |
| four serial phlebotomy procedures each followed by intravenous infusion to replete lost iron | No effect - did not alter | vascular endothelial function in the brachial artery | Human | iron-replete, non-anemic subjects | Not specified (iron supplementation was administered intravenously to replete lost iron, but exact dosage not detailed) | Effects of serial phlebotomy on vascular endothelial function: Results of a prospective double-blind randomized study.cited 8× |
| iron deficiency (ID) | Decreases - leading to | cardiac function impairment | Human | — | Not specified | Iron and cardiovascular health: A review. |
| iron deficiency (ID) | Decreases - reduced | mitochondrial function | Human | — | Not specified | Iron and cardiovascular health: A review. |
| Iron deficiency (ID) | Decreases - causing deleterious effects that include decreases | cognitive function | Animal | — | Not specified | The effects of an essential fatty acid compound and a cholecystokinin-8 antagonist on iron deficiency induced anorexia and learning deficits.cited 11× |
| iron deficiency | Decreases - decline | function of the basal ganglia | Human | — | Not specified | Iron Deficiency, Cognitive Functions, and Neurobehavioral Disorders in Children.cited 121× |
| iron deficiency | Decreases - serious consequences | immune function | Human | — | Not specified | Nutritional iron deficiency: the role of oral iron supplementation.cited 14× |
| iron deficiency | Decreases - severe impairment | immune function | Human | — | Not specified | Nutritional iron deficiency: the role of oral iron supplementation.cited 14× |
| iron deficiency | Decreases - associated with worsened clinical outcomes | right ventricular function | Human | patients with PH | Not specified | Iron Deficiency in Pulmonary Hypertension. |
| excess iron | Decreases - compromising | muscle function and recovery | Human | — | Not specified | The IRONy in Athletic Performance.cited 7× |
| folate, iodine and iron intake during pregnancy | No effect - impacts on | foetal brain development and cognitive function | Human | — | Not specified | Effects of Nutritional Interventions during Pregnancy on Infant and Child Cognitive Outcomes: A Systematic Review and Meta-Analysis.cited 32× |
| iron therapy | Increases - improves | cardiac function | Human | patients with CHF with ID and anaemia | Not specified | Efficacy and safety of iron therapy in patients with chronic heart failure and iron deficiency: a systematic review and meta-analysis based on 15 randomised controlled trials.cited 13× |
| low-molecular weight iron dextran (1000 mg) | Increases - to measure the effect of | translational measures of immune cell function | Human | traumatically injured orthopaedic patients with acute blood loss anaemia | Single dose infusion of low-molecular weight iron dextran (1000 mg). | Role of single-dose intravenous iron therapy for the treatment of anaemia after orthopaedic trauma: protocol for a pilot randomised controlled trial.cited 1× |
| iron deficiency within the cell | Decreases - impaired | biological function of mitochondria | HumanMolecular | fungal cells | Not specified | Berberine disrupts the high-affinity iron transport system to reverse the fluconazole-resistance in Candida albicans. |
| maternal iron status | No effect - found no association | cognitive function | Human | children | Not specified | Association between maternal nutritional status in pregnancy and offspring cognitive function during childhood and adolescence; a systematic review.cited 84× |
| iron status | No effect - may influence | outcomes through modulation of the pulmonary circulation as well as myocardial and skeletal muscle function | Human | — | Not specified | Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target.cited 83× |
| Zinc, copper, selenium and iron | Increases - are involved in | the correct development and function of the immune system | Human | — | Not specified | Immunomodulatory diet in pediatric age.cited 3× |
| Selenium, calcium, magnesium, zinc, and iron | Increases - show the potential to enhance | immune function | Human | patients with IBD | Not specified | Nutritional Support: The Use of Antioxidants in Inflammatory Bowel Disease.cited 4× |